Armata Secures First Phase 3 War Department Funding for AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has secured $3.7 million in non-dilutive funding from the U.S. Department of War to begin execution of the Phase 3 clinical program for AP-SA02. This initial tranche brings the total federal support for the bacteriophage candidate to approximately $32.4 million. The next confirmable milestone is the initiation of the Phase 3 superiority study, which the company anticipates will commence in the second half of 2026.

The new funding is the first specifically allocated for Phase 3 activities under a previously announced award from the Medical Technology Enterprise Consortium. The award is managed by the Naval Medical Research Command and funded through the Defense Health Agency and Joint Warfighter Medical Research Program. This addition follows $28.7 million in prior disbursements. The cumulative $32.4 million supports the advancement of AP-SA02 for the adjunctive treatment of complicated Staphylococcus aureus bacteremia, covering both methicillin-sensitive and methicillin-resistant strains.

Supply Chain and Regulatory Status

AP-SA02 is a fixed multi-phage cocktail designed to complement existing antibiotic therapy. The U.S. Food and Drug Administration has granted the candidate three designations: Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy. Positive results from the Phase 2a diSArm study were presented as a late-breaking oral presentation at IDWeek in October 2025. The company maintains in-house current Good Manufacturing Practices (cGMP) facilities to support the production of its phage-based therapeutics, ensuring control over the manufacturing pipeline as the program scales toward pivotal trials.

What to Watch Next

Dr. Deborah Birx, Chief Executive Officer of Armata, stated that the Department of War has supported the program through multiple development stages and that these new funds extend that support into Phase 3. She noted the company intends to continue working closely with the Department of War regarding potential additional support as the study advances. For the setup, the focus shifts to the physical initiation of the Phase 3 superiority study. Investors should watch for the definitive agreement or filing that confirms the start of patient enrollment in the second half of 2026. The tape will likely react to any updates on the manufacturing capacity required to supply the pivotal trial and the specific terms of any further non-dilutive commitments from federal partners.